(Total Views: 739)
Posted On: 06/07/2022 7:44:48 AM
Post# of 148899
Taken from here: https://www.astrazeneca.com/content/astraz/me...cer.html#!
These statements:
These statements are made because they found that this therapy was beneficial in hormone-receptor negative disease. Therefore, they feel that although it has BTD in HER-2 low disease, it may also be applicable in HR negative disease. A portion of HR negative disease is triple negative disease. The statements are made based on the result in the trial where out of the 557 total patients, 58 were HR negative, how many were triple negative? maybe 20, just guessing.
So in a similar fashion, as Astra is pursuing the eradication of the division of Breast cancer saying that it should not be divided as hormone positive or hormone negative , but just give everyone with HER-2 low or HER-2 negative Enhertu early, (this is still not triple negative, but some triple negative were likely in their study) , and the patients will fare as good as possible, However, with the triple negative work Jangsoon Lee at MD Anderson, with LL and PD-1 inhibitors, the HER-2 hormone classification won't be the criteria, rather, the division will be based on the cancer's +/- dependence on the chemokine receptor CCR5 for it's chemical communication, whether necessary or not, that insures it's survival.
It's in the chemical communication of the Tumor Micro Environment.
These statements:
Quote:
Shanu Modi, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, US and Principal Investigator for the trial, said: “The results of DESTINY-Breast04 show for the first time that a HER2-directed therapy can provide a survival benefit to patients with low HER2 expression, indicating we must reconsider the way we categorise patients with metastatic breast cancer. The efficacy seen with Enhertu also reinforces the potential to establish a new standard of care for more than half of all patients with breast cancer currently categorised as having HER2-negative disease, but who actually have tumours with low HER2 expression.”
Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca said: “Today’s results represent a pivotal moment demonstrating the potential for Enhertu to redefine the treatment of HER2-targetable cancers . DESTINY-Breast04 validates targeting the lower end of the spectrum of HER2 expression, since Enhertu reduced the risk of disease progression or death across all types of patients in the trial by half, and reduced the risk of death by over a third. We must now evolve the way we classify and treat metastatic breast cancer to ensure these patients are effectively diagnosed and treated.”
These statements are made because they found that this therapy was beneficial in hormone-receptor negative disease. Therefore, they feel that although it has BTD in HER-2 low disease, it may also be applicable in HR negative disease. A portion of HR negative disease is triple negative disease. The statements are made based on the result in the trial where out of the 557 total patients, 58 were HR negative, how many were triple negative? maybe 20, just guessing.
So in a similar fashion, as Astra is pursuing the eradication of the division of Breast cancer saying that it should not be divided as hormone positive or hormone negative , but just give everyone with HER-2 low or HER-2 negative Enhertu early, (this is still not triple negative, but some triple negative were likely in their study) , and the patients will fare as good as possible, However, with the triple negative work Jangsoon Lee at MD Anderson, with LL and PD-1 inhibitors, the HER-2 hormone classification won't be the criteria, rather, the division will be based on the cancer's +/- dependence on the chemokine receptor CCR5 for it's chemical communication, whether necessary or not, that insures it's survival.
It's in the chemical communication of the Tumor Micro Environment.
(2)
(0)Scroll down for more posts ▼
